cybcin
cybininc
Cybin Inc operates as a clinical-stage biopharmaceutical company developing psychedelic-based therapeutics for mental healthcare. The company trades under the ticker CYBN on the NEO Exchange and received final approval to begin trading on the NYSE American on or about August 5. Cybin closed an oversubscribed private placement of U.S. $150 million in March 2024 and announced a $175 million registered direct offering. Cybin is transitioning to the name Helus Pharma as part of a move of its shares to a different stock exchange.
Links for cybcin
No links for cybcin yet. Have one? Submit it from this profile.
Similar profiles
People browsed alongside cybcin.
